TREANDA New Drug Application For The Treatment Of Chronic Lymphocytic Leukemia Granted Priority Review Status By FDA
Dec 6th 2007Drug InformationLymphoma / Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review designation to the TREANDA(R) (bendamustine HCl) New Drug Application (NDA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL). CLL is a slowly progressing blood and bone marrow disease with an estimated 15,000 new cases diagnosed every year in the United States. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
